中文名 | Verdinexor (KPT-335) |
英文名 | Verdinexor (KPT-335) |
别名 | 化合物VERDINEXOR SINE抑制剂(VERDINEXOR) (Z)-3(3-(3,5-双(三氟甲基)苯基)-1H-1,2,4-三唑-1-基)-N'-(吡啶-2-基)丙烯酰肼 |
英文别名 | CS-1798 KPT-335 Verdinexor Verdinexor(KPT-335) Verdinexor (KPT-335) Z)-3-(3-(3,5-bis(trifluoroMethyl)phenyl)-1H-1,2,4-triazol-1-yl)-N'-(pyridin- (KPT335)(Z)-3-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-N'-(pyridin-2-yl)acrylohydrazide (2Z)-3-[3-[3,5-bis(trifluoromethyl)phenyl]-1H-1,2,4-triazol-1-yl]- 2-propenoic acid-2-(2-pyridinyl)hydrazide (2Z)-3-(3-(3,5-Bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-N -(pyridin-2-yl)prop-2-enehydrazide Verdinexor(KPT-335) |
CAS | 1392136-43-4 |
化学式 | C18H12F6N6O |
分子量 | 442.32 |
密度 | 1.49±0.1 g/cm3(Predicted) |
酸度系数 | 10.04±0.43(Predicted) |
存储条件 | -20℃ |
体外研究 | Verdinexor inhibits the viability of Jurkat, OCI-Ly3, OCI-Ly10, and CLBL1 cells with IC50 of 0.3 nM, 2.1 nM, 41.8 nM, and 8.5 nM, respectively. KPT-335 also induces apoptosis in CLBL1 cells and primary canine DLBCL cells that express XPO1 and SINE. Verdinexor potently and selectively inhibits vRNP export and effectively inhibits the replication of various influenza virus A and B strains, including pandemic H1N1 virus, highly pathogenic H5N1 avian influenza virus, and the recently emerged H7N9 strain. Verdinexor抑制Jurkat,OCI-Ly3,OCI-Ly10,和CLBL1细胞的活性,IC50分别为0.3 nM,2.1 nM,41.8 nM,和8.5 nM。KPT-335也会诱导表达XPO1与SINE 的CLBL1和原代犬DLBCL细胞凋亡。 Verdinexor选择性有效抑制vRNP输出,也有效抑制各种流感病毒A和B菌株,包括流行性H1N1病毒,高致病性H5N1禽流感病毒,以及最近出现的H7N9菌株。 |
体内研究 | Verdinexor (25 mg/kg twice daily, p.o.) reduces proinflammatory cytokine expression in the lung, produces in vivo antiviral activity by reducing lung virus titers, and thus reduces pulmonary disease pathogenesis and death associated with lethal influenza A virus challenge. In autosomal-dominant polycystic kidney disease model, Verdinexor (5 mg/kg, i.p.) attenuates cyst growth via inhibition of XPO1. Verdinexor (25 mg/kg,每天两次,p.o.)降低肺中促炎性细胞因子的表达,在体内通过减少肺病毒滴度产生抗病毒活性,并且因此降低与致死性甲型流感A病毒相关的肺疾病的发病率和死亡率。 在常染色体显性多囊肾疾病模型中,Verdinexor (5 mg/kg, i.p.)通过抑制XPO1减弱囊肿生长。 |
上游原料 | 3-(3,5-双(三氟甲基)苯基)-1H-1,2,4-三唑 |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 2.261 ml | 11.304 ml | 22.608 ml |
5 mM | 0.452 ml | 2.261 ml | 4.522 ml |
10 mM | 0.226 ml | 1.13 ml | 2.261 ml |
5 mM | 0.045 ml | 0.226 ml | 0.452 ml |
微信搜索化工百科或扫描下方二维码,添加化工百科小程序,随时随地查信息!